The disposition of fazadinium was studied in 10 patients with normal hepatic and renal function undergoing abdominal surgery. The serum and urinary concentrations were determined fluorimetrically. A single dose of fazadinium 1.5 mg kg~l was administered i.v. The plasma decay curve for fazadinium was found to be diphasic and the data were interpreted according to a two-compartment open model. The half-lives of the distribution and elimination phases were 12.3 and 76.4 min respectively. The total apparent volume of distribution averaged 234 ml kg-1 and the plasma clearance 132 ml min" 1 . From these results it is suggested that fazadinium should have a shorter duration of action than other non-depolarizing agents because of the more rapid decline of the serum concentration corresponding mainly to the short half-life of the /3 phase. This rapid elimination phase of fazadinium did not correspond to an extensive biotransformation because fazadinium was excreted almost unchanged in the urine and this excretion accounted for 50% of the injected dose within 24 h.
It is known that the duration of action of fazadinium is shorter than that of the longer established nondepolarizing agents tubocurarine and pancuronium in several animal species (Bolger et al., 1972; Simpson et al., 1972; Brittain and Tyers, 1973) . This was not so in primates, including man (Arora et al., 1973; Blogg et al., 1973; Brittain and Tyers, 1973; Kean, 1975) . It is now recognized that the duration of action of nondepolarizing muscle relaxants is governed by the profile of the plasma decay curve. Thus it has become apparent that inter-species variation in drug responses may be attributable to differences in the rates and routes by which these drugs are excreted and metabolized (Savarese and Kitz, 1975) . Fazadinium also differs from tubocurarine and pancuronium in its chemical configuration which makes it more susceptible to metabolic breakdown; the molecule has been shown to be split by rat liver microsomal azoreductase (Bolger et al., 1972) . This biotransformation producing inactive metabolites (Srinivasan, Wahdi and Pleuvry, 1973) may influence the duration of action of fazadinium as compared with other non-depolarizing drugs which either are not metabolized extensively, such as tubocurarine and gallamine, or whose metabolites remain active, such as pancuronium .
The aim of the present work was to study the pharmacokinetics of fazadinium in anaesthetized patients. Correspondence to P.D.
0007-0912/78/0050-0773 $01.00
METHODS
Ten patients undergoing general anaesthesia for a variety of surgical procedures (table I) were studied. None of the patients had any clinical or biochemical evidence of hepatic or renal damage. The same anaesthetic procedure was used for all patients. Atropine 0.5 mg and droperidol 7.5 mg were given i.m. as premedication. Thiopentone 6-9 mg kg" 1 was given to induce anaesthesia. Suxamethonium 0.8 mg kg" 1 i.v. was given to facilitate tracheal intubation. Anaesthesia was maintained with 60% nitrous oxide in oxygen; the injection of phenoperidine 15 y.g kg" 1 was repeated every 30 min. Ventilation of the lungs was controlled throughout the surgical procedure. After full recovery from the effects of suxamethonium a single dose of fazadinium 1.5 mg kg-1 was given i.v. In two patients only, atropine 0.5 mg and neostigmine Venous blood was sampled (5 ml) at 5, 10, 15, 30, 60, 90, 120, 150, 180, 210, 240, 270 and 300 min following the administration of fazadinium. Urine samples were collected for up to 24 h. For the estimation of fazadinium in the serum, a small modification of the fluorimetric method employed for the determination of pancuronium-like compounds was used: the concentration of the fluorescent dye, rose-bengal, was increased from 200 (xg ml" 1 to 500 \Lg ml" 1 . With this change, the lowest serum concentration of fazadinium that could be determined reliably was 0.05 fig ml" 1 . The concentrations of fazadinium in urine samples were determined using a different fluorimetric method developed by A. M. Pastorino (Glaxo Laboratories, Verona, Italy; personnal communication). This method is based on the addition of an alkali to urine samples leading to the breakdown of the azobridge of fazadinium and formation of 3-methyl-2-phenylimidazo-(l, 2a)-pyridine, which is one of the major metabolites of fazadinium (Bolger et al., 1972) . Calibration standards of fazadinium in urine over a range of 0.4-4 ;xg ml" 1 were prepared: 0.5 ml of each sample was added to silanized stoppered glass tubes. Two millilitre of sodium hydroxide 0.1 mol litre" 1 was added to each tube and the tubes heated at 50° C for 60 min. After cooling to room temperature, cyclohexane 4.0 ml was added and the tubes mixed on a rotary mixer for 5 min and then centrifuged at 2000 rev min"
1 for 5 min. The aqueous phase was discarded and the fluorescence determined in the organic phase (excitation: 325 nm, emission: 390 nm), using an Aminco-Bowman spectrophotofluorimeter. The concentration of fazadinium was linear over the range of calibration standards used. For the direct determination of metabolites in urine, sodium hydroxide 0.1 mol litre" 1 was replaced by sodium chloride 0.1 mol litre" 1 and heating was omitted. The plasma concentration-time data were analysed according to a two-compartment open model (Riegelman, Loo and Rowland, 1968) which has been used previously to describe the pharmacokinetics of pancuronium (McLeod, Watson and Rawlins, 1976) . The pharmacokinetic variables which were measured were the volumes of the central (F x ) and of the peripheral compartments (K 2 ), the rate constants for the transfer of the drug from the central to the peripheral compartment (& 12 ) and from the peripheral to the central compartment (& 21 ) and the rate constant corresponding to elimination from the central compartment (& EIi ). The serum half-lives corresponding to the distribution or a phase (^ a) and to the elimination or p phase (t i (i) were estimated by non-linear iterative curve fitting. The total apparent volume of distribution (F d ) and the clearance (Cl) were determined by the area method (Greenblatt and KochWeser, 1975) . Computation was done on a HewlettPackard 9820 A digital calculator.
RESULTS
The serum concentration of fazadinium showed an initial rapid decrease followed by a more gradual reduction ( fig. 1) . The patients were able to breathe without ventilatory support or a neuromuscular blocking antagonist 160 ±11 min after the injection of fazadinium. At this time, the mean plasma concentration was 1.25 ± 0.12 y.g ml" 1 in the eight patients who did not receive neostigmine. It appears that, 90 min after administration of fazadinium, the reduction in the plasma concentration is monoexponential ( fig. 1) 
±0.011
The urine excretion of fazadinium was monitored in all patients for 24 h (table IV). The amount of fazadinium excreted in the urine during 24 h averaged 50 + 3% of the injected dose. This excretion occurred mainly during the first 12 h. In two subjects for whom urine collection was obtained during the first 6 h, 47% and 35% of the injected dose were recovered in the urine. Only 4% of the injected dose was excreted between 12 and 24 h. Fazadinium was excreted essentially unchanged in the urine. Only trace amounts of metabolites, accounting for no more than 3% of the injected dose, were detected in all cases. The interpretation of the data according to a twocompartment open model appears reasonable since the plasma decay curve was linear between 90 and 300 min. This model has been proposed previously for other non-depolarizing muscle relaxants such as alcuronium (Raaflaub and Frey, 1972) , gallamine (Duvaldestin et al., 1977) and pancuronium (McLeod, Watson and Rawlins, 1976; Somogyi, Shanks and Triggs, 1976) . Compared with the other nondepolarizing muscle relaxants, the decrease of the plasma concentration of fazadinium is more rapid. This is a result of a shorter (3 half-life of about 76 min for fazadinium, whereas t± (3 values are 132 min for pancuronium (Somogyi, Shanks and Triggs, 1976) , 128 min for gallamine (Duvaldestin et al., 1977) and 200 min for alcuronium (Raaflaub and Frey, 1972) . The /? phase is determined by renal and biliary excretion and also by metabolic breakdown. The amount of fazadinium excreted in the urine is similar to that observed with pancuronium in man since one-half of the dose of pancuronium was also found to be excreted in the urine within 24 h . This excretion consisted mainly of unchanged fazadinium, and metabolites accounted for no more than 3% of the injected dose in any case of the present study. Thus, the short half-life of the elimination phase cannot be explained by extensive metabolic breakdown of the molecule in vivo. These results are in agreement with a previous report which showed that urinary excretion of fazadinium in man occurred mainly as unchanged drug (Blogg et al., 1973) . Increased biliary elimination of fazadinium as compared with other muscle relaxants is therefore a possible explanation of this shorter elimination phase. The rate of decay of plasma concentration influences markedly the duration of action of muscle relaxants. Therefore it is predictable, from the present results, that fazadinium should have a shorter duration of action than other non-depolarizing agents, especially when high single or cumulative doses are administered. It is known that the decrease of plasma concentration is influenced mainly by tissue distribution at low doses and by the rate of excretion or biotransformation at high doses. This prediction of a short duration of action for fazadinium contrasts with the conclusions of preliminary clinical trials which are open to question for two main reasons. Volatile anaesthetic agents, which are known to increase the effect of muscle relaxants (Miller et al., 1972) , were administered simultaneously with fazadinium (Simpson et al., 1972; Arora et al., 1973; Kean, 1975) . Equipotency between fazadinium and other muscle relaxants was not defined, thus making comparison difficult. It has been suggested that fazadinium is three times less potent than tubocurarine. This was determined by comparing the receptor dissociation constants {Kb) of the two agents in the isolated guineapig lumbrical muscle (Waud, 1977) . Relative potencies of different muscle relaxants can be quantified from the comparison either of their dose-response curves or of their serum concentration for a similar degree of neuromuscular blockade. Thus, further investigations would be needed, in addition to pharmacokinetic studies in order to predict the duration of action of fazadinium in man. Waud, B. E. (1977) 
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SUMARIO
Se estudio la composition de fasadinio en 10 pacientes con funciones hepaticas y renales normales, que se sometian a cirujia abdominal. Las concentraciones de suero y urina se determinaron fluorimetricamente. Se administro intravenosamente una sola dosis de fasadinio 1,5 mg kg" 1 . Se descubrio que la curva de decaimiento del fasadinio es difasica y los datos fueron interpretados de acuerdo con un modelo abierto de dos compartimentos. Los periodos de vida media de las fases de distribuci6n y elimination fueron de 12,3 y 76,4 min, respectivamente. El volumen aparente total de la distribution promedid 234 ml kg" 1 y la eliminaci6n de plasma, 132 ml min" 1 . Tomando como base estos resultados, se sugiere que el fasadinio actua durante un periodo mas corto que los otros agentes no-depolarizantes, por la disminucion mas rapida de la concentracion de suero que corresponde principalmente al periodo corto de vida media de la fase (3. Esta fase de eliminaci6n rapida del fasadinio no corresponde a una biotransformaci6n extensa, porque el fasadinio fue excretado casi sin cambio en la orina, y dentro de un periodo de 24 h esta excreci6n fue de 50% de la dosis inyectada.
